Cover Image
市場調查報告書

Ziarco Pharma Ltd:產品平台分析

Ziarco Pharma Ltd - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 285617
出版日期 內容資訊 英文 27 Pages
訂單完成後即時交付
價格
Back to Top
Ziarco Pharma Ltd:產品平台分析 Ziarco Pharma Ltd - Product Pipeline Review - 2015
出版日期: 2015年12月16日 內容資訊: 英文 27 Pages
簡介

Ziarco Pharma Ltd 是提供氣喘、慢性閉塞性肺疾病、過敏性鼻炎、肺纖維化等多種發炎疾病及過敏疾病治療藥的生物科技企業。該公司同時也提供異位性皮膚炎、乾癬、急性/慢性皮膚瘙癢、發炎性疾病等皮膚相關症狀之治療藥。

本報告提供Ziarco Pharma Ltd的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,同時也提供最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Ziarco Pharma Ltd的基本資料

Ziarco Pharma Ltd概要

  • 主要資訊
  • 企業資料

Ziarco Pharma Ltd:R&D概要

  • 主要的治療範圍

Ziarco Pharma Ltd:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Ziarco Pharma Ltd:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Ziarco Pharma Ltd:藥物簡介

  • ZPL-3893787
  • ZPL-5212372
  • Small Molecules to Inhibit Histamine H3 Receptor for Nasal Congestion and Allergic Rhinitis
  • Small Molecules to Inhibit Histamine H4 Receptor for Allergies and Inflammation
  • ZPL-868087
  • Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders

Ziarco Pharma Ltd:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Ziarco Pharma Ltd:最近的開發平台趨勢

Ziarco Pharma Ltd:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • ZPL-3893787
    • ZPL-5212372

Ziarco Pharma Ltd:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07867CDB

Summary

Global Markets Direct's, 'Ziarco Pharma Ltd - Product Pipeline Review - 2015', provides an overview of the Ziarco Pharma Ltd's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ziarco Pharma Ltd's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ziarco Pharma Ltd including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ziarco Pharma Ltd's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ziarco Pharma Ltd's pipeline products

Reasons to buy

  • Evaluate Ziarco Pharma Ltd's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ziarco Pharma Ltd in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ziarco Pharma Ltd's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ziarco Pharma Ltd and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ziarco Pharma Ltd
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ziarco Pharma Ltd and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ziarco Pharma Ltd Snapshot
    • Ziarco Pharma Ltd Overview
    • Key Information
    • Key Facts
  • Ziarco Pharma Ltd - Research and Development Overview
    • Key Therapeutic Areas
  • Ziarco Pharma Ltd - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ziarco Pharma Ltd - Pipeline Products Glance
    • Ziarco Pharma Ltd - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ziarco Pharma Ltd - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Ziarco Pharma Ltd - Drug Profiles
    • ZPL-3893787
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPL-5212372
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ZPL-868087
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit Spleen Tyrosine Kinase for Allergic Inflammatory Disorders
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ziarco Pharma Ltd - Pipeline Analysis
    • Ziarco Pharma Ltd - Pipeline Products by Target
    • Ziarco Pharma Ltd - Pipeline Products by Route of Administration
    • Ziarco Pharma Ltd - Pipeline Products by Molecule Type
    • Ziarco Pharma Ltd - Pipeline Products by Mechanism of Action
  • Ziarco Pharma Ltd - Recent Pipeline Updates
  • Ziarco Pharma Ltd - Dormant Projects
  • Ziarco Pharma Ltd - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • ZPL-3893787
      • ZPL-5212372
  • Ziarco Pharma Ltd - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ziarco Pharma Ltd, Key Information
  • Ziarco Pharma Ltd, Key Facts
  • Ziarco Pharma Ltd - Pipeline by Indication, 2015
  • Ziarco Pharma Ltd - Pipeline by Stage of Development, 2015
  • Ziarco Pharma Ltd - Monotherapy Products in Pipeline, 2015
  • Ziarco Pharma Ltd - Phase II, 2015
  • Ziarco Pharma Ltd - Phase I, 2015
  • Ziarco Pharma Ltd - Preclinical, 2015
  • Ziarco Pharma Ltd - Discovery, 2015
  • Ziarco Pharma Ltd - Pipeline by Target, 2015
  • Ziarco Pharma Ltd - Pipeline by Route of Administration, 2015
  • Ziarco Pharma Ltd - Pipeline by Molecule Type, 2015
  • Ziarco Pharma Ltd - Pipeline Products by Mechanism of Action, 2015
  • Ziarco Pharma Ltd - Recent Pipeline Updates, 2015
  • Ziarco Pharma Ltd - Dormant Developmental Projects,2015
  • Ziarco Pharma Ltd - Discontinued Pipeline Products, 2015

List of Figures

  • Ziarco Pharma Ltd - Pipeline by Top 10 Indication, 2015
  • Ziarco Pharma Ltd - Pipeline by Stage of Development, 2015
  • Ziarco Pharma Ltd - Monotherapy Products in Pipeline, 2015
  • Ziarco Pharma Ltd - Pipeline by Top 10 Target, 2015
  • Ziarco Pharma Ltd - Pipeline by Top 10 Route of Administration, 2015
  • Ziarco Pharma Ltd - Pipeline by Top 10 Molecule Type, 2015
  • Ziarco Pharma Ltd - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top